Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1161-1180 of 1,694 trials

Heart Health: Apixaban vs. Warfarin Study

We are comparing two medications to see which is more effective in resolving blood clots in patients with left ventricular thrombus after a heart attack. We're also looking at safety and bleeding risks associated with each treatment.

Acute Myocardial InfarctionLeft Ventricular Thrombosis3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Metastatic Colorectal Cancer: Valproic Acid and Standard Treatment

We are studying a new combination of Valproic acid with standard therapies for patients with metastatic colorectal cancer who have already been treated. The goal is to see if this combination improves survival and quality of life compared to standard treatment alone.

Metastatic Colorectal Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Fibrotic Lung Disease: Wharton's Jelly Stem Cells

We are studying the safety and effects of a stem cell treatment for people with fibrotic interstitial lung diseases. This research aims to see if it can improve lung function and quality of life.

Interstitial Lung Disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicinePulmonology

Epcoritamab for Relapsed Large B-Cell Lymphoma

We are studying the effectiveness of Epcoritamab as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma. This trial aims to see how well it works and how safe it is compared to other treatments.

Diffuse Large B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Cognitive Dysfunction in Schizophrenia: Clemastine and Exercise Study

We are investigating whether combining Clemastine with aerobic exercise can improve cognitive function in people with schizophrenia. The study aims to see if this approach enhances memory and overall functioning.

Schizophrenia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

AMG 193 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, AMG 193, for patients with advanced non-small cell lung cancer that has a specific genetic deletion. The trial aims to evaluate its safety and effectiveness compared to existing options.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced NSCLC: MCLA-129 Treatment Study

We are evaluating a new bispecific antibody, MCLA-129, for patients with advanced non-small cell lung cancer. The study aims to assess its effectiveness and safety compared to standard treatments.

Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Wart Treatment: 2LVERU® JUNIOR and 2LVERU®

We are studying whether two new treatments can help people with warts get rid of them more effectively than a placebo. The trial will also look at pain levels and safety during treatment.

Warts>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesDermatologyInfectious Diseases

Breast Cancer: Shorter Hormone Therapy Duration

We are studying whether limiting hormone therapy to 2 years is effective for women with hormone-sensitive breast cancer at very low risk of recurrence. This trial aims to assess the safety and quality of life during and after treatment.

Localized Luminal A Breast Cancer in Post-Menopausal Women>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

Compulsive Sexual Behavior Disorder: Medication Study

We are comparing the effects of escitalopram, naltrexone, and their combination on symptoms of compulsive sexual behavior. This study aims to understand how these treatments may improve daily functioning and emotional well-being.

Compulsive Sexual Behavior3-6 monthsConfirmation phase (III)Investigational MedicinesPsychiatry

Focal Onset Seizures: Extended-Release Levetiracetam Study

We are testing a new once-daily version of levetiracetam for people with drug-resistant focal onset seizures. The study aims to see if it reduces seizure frequency better than current treatments and a placebo.

Refractory Epilepsy3-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Heart Failure Risk: Baxdrostat with Dapagliflozin

We are studying whether the combination of baxdrostat and dapagliflozin can lower the risk of heart failure and cardiovascular death in people at increased risk. This trial compares this combination to dapagliflozin alone.

Heart Failure Signs and Symptoms>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCardiologyInternal Medicine

Acute Myeloid Leukemia: Low Intensity Therapy Study

We are exploring whether a gentler treatment approach helps patients with relapse or refractory acute myeloid leukemia live longer and feel better compared to stronger therapies.

Acute Myeloid LeukemiaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Familial Hypercholesterolemia: Inclisiran vs. Alirocumab

We are comparing two new treatments, inclisiran and alirocumab, to standard therapy for children with heterozygous familial hypercholesterolemia. The goal is to see which treatment better lowers cholesterol levels and improves quality of life.

Heterozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyEndocrinology

Severe Vitamin D Deficiency: New Treatment Study

We are investigating a new treatment for people with severe vitamin D deficiency to see if it effectively raises vitamin D levels compared to another option. The study will also look at safety and patient satisfaction.

Severe Vitamin D Deficiency≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyInternal Medicine

APL-101 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, APL-101, for patients with advanced solid tumors, including non-small cell lung cancer with specific genetic mutations. The trial aims to assess its safety and effectiveness, as well as find the best dose.

Non-Small Cell Lung CancerCentral Nervous System NeoplasmSolid Tumors>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

OMX-0407 for Unresectable Solid Tumors

We are studying a new medication, OMX-0407, in patients with previously treated solid tumors to see how well it works and to find the safest dose. This trial will help us understand its effects on cancer response and patient quality of life.

Previously Treated Unresectable Solid Tumours>2 yearsSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Focal Seizures: PRAX-628 Study

We are testing a new medication, PRAX-628, for adults with focal seizures to see if it can reduce seizure frequency compared to a placebo. The study also looks at the safety and tolerability of this treatment.

Focal EpilepsyEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Colon Cancer: New Treatment with PIPAC

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard treatments improves outcomes for patients with advanced colon cancer that has spread to the abdomen. This trial will help us understand its effects on survival and quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Thyroid Cancer Treatment: Radioiodine Strategies

We are comparing two treatment strategies for intermediate-risk differentiated thyroid cancer patients to see which is more effective. This study will also evaluate patient quality of life and side effects over time.

Thyroid Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology